Announcement PDF Dr Amy Pearlman Joins LTR Pharma’s Scientific Advisory Board for US Market Entry 11 August 2025 Highlights • Leading US erectile dysfunction specialist Dr Amy Pearlman joins LTR Pharma's Scientific Advisory Board to accelerate prescriber adoption ahead of 2026 launch. • Appointment supports planned US launch of ROXUS® in H1 CY2026 with Dr Pearlman to advise on medical education and prescriber engagement strategies. • Strategic addition strengthens US market entry capabilities for ROXUS® and SPONTAN®, targeting the US$3.7 billion1 erectile dysfunction market. LTR Pharma Limited (ASX:LTP) (“LTR Pharma” or “the Company”) is pleased to announce that Dr Amy Pearlman, M.D., a board-certified urologist and nationally recognised leader in sexual medicine, has joined LTR Pharma's Scientific Advisory Board ("SAB"). As a member of LTR Pharma's SAB, Dr Pearlman will provide strategic clinical insight, medical engagement, and market access strategies for SPONTAN® and ROXUS®, the Company's innovative nasal spray treatments for erectile dysfunction. Dr Pearlman is Co-founder of Prime Institute in Coral Gables, Florida, a premium private medical practice focused on optimising cardiometabolic, hormonal, and sexual health in men and women. She is a former Director of the Men's Health Program at the University of Iowa and a fellowship-trained specialist in male sexual and hormonal health. She completed her undergraduate education at the University of Miami, earned her medical degree from Baylor College of Medicine, completed her urology residency at the University of Pennsylvania, and pursued fellowship training in men's health, genitourinary reconstruction, and male infertility at Wake Forest University. Her distinguished career includes serving as a board member for the Sexual Medicine Society of North America and currently serving on the editorial board for the Urology Times. She is also an active member of the American Urological Association (AUA). Her clinical expertise encompasses both medical and surgical management of erectile dysfunction, ejaculatory disorders, penile curvature, testosterone deficiency, penile enhancement, and female sexual dysfunction. As a prominent voice in sexual health innovation, Dr Pearlman brings extensive expertise in erectile dysfunction treatment, testosterone optimisation, and comprehensive approaches to sexual wellness. She has contributed to the Fifth International Consultation on Sexual Medicine (ICSM 2024), shaping global policy and recommendations in sexual health alongside leading international experts. Dr Pearlman's appointment significantly enhances LTR Pharma's clinical expertise as it prepares for expansion into the US market. Her deep understanding of the American healthcare landscape, established relationships with key opinion leaders, and a proven record in advancing innovative treatments will be instrumental in positioning 1800 519 711 | ltrpharma.com | investors@ltrpharma.com LTR Pharma Limited (ABN 64 644 924 569 / ACN 644 924 569) SPONTAN and ROXUS for success in North America. She will play a pivotal role in building prescriber awareness for the Company’s rapid-onset ED treatments. Her thought leadership is widely recognised through national media appearances, conference presentations, and her popular podcast "Pearls and Perspectives". Dr Pearlman has been honoured with international professorships and is frequently invited as a keynote speaker at major urological and sexual medicine conferences globally. Dr Amy Pearlman, said: "I believe SPONTAN and ROXUS will be important additions to treatment options in the United States for men seeking effective, rapid-onset erectile dysfunction treatment. The intranasal delivery platform offers a compelling alternative to current oral medications, providing onset of action in 10 minutes or less with an excellent safety profile. Having dedicated my career to advancing sexual health and wellness, I'm thrilled to join LTR Pharma's Scientific Advisory Board and contribute to bringing these innovative treatments to American patients who deserve better options for spontaneous intimacy." LTR Pharma Executive Chairman, Lee Rodne, said: "We are honoured to welcome Dr Pearlman to our Scientific Advisory Board. Her recognised expertise in sexual medicine, combined with her innovative approach to patient care and treatment, makes her an invaluable addition to our team. Dr Pearlman's appointment is a critical milestone in our US market entry strategy, with ROXUS planned for launch in H1 CY2026. Her relationships with prescribers and her influential position within the American urological and sexual health community will be crucial as we build momentum in the world's largest pharmaceutical market. Her appointment underscores our commitment to assembling world-class expertise to deliver innovative treatments for erectile dysfunction." 1 Source: Frost and Sullivan Report, The Erectile Dysfunction Medicines Market, September 2023 - ENDS – This announcement has been approved by the Board of Directors. 1800 519 711 | ltrpharma.com | investors@ltrpharma.com LTR Pharma Limited (ABN 64 644 924 569 / ACN 644 924 569) About LTR Pharma LTR Pharma is an emerging pharmaceutical company committed to developing and commercialising innovative therapies that address significant unmet medical needs. The Company is leveraging its proprietary intranasal drug delivery platform to enable rapid, non-invasive treatment options across multiple therapeutic areas. LTR’s lead products, SPONTAN® and ROXUS®, are fast-acting intranasal sprays for the treatment of erectile dysfunction, enabling onset of action in 10 minutes or less. Building on this proven technology, the Company is now advancing OROFLOW®, a novel intranasal spray under development for the treatment of Oesophageal Motility Disorders (OMD) – a debilitating group of conditions affecting swallowing function. Through strategic partnerships, LTR Pharma is expanding its pipeline and global footprint to deliver differentiated, patient-centric treatments that enhance quality of life. For further information please contact: Media enquiries Haley Chartres haley@hck.digital Investor enquiries Peter McLennan investors@ltrpharma.com 1800 519 711 | ltrpharma.com | investors@ltrpharma.com LTR Pharma Limited (ABN 64 644 924 569 / ACN 644 924 569)